Efficacy for treating MM with DPP8/9 inhibitor.

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K06875
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Tumor therapeutics
• Research Institution: Sapporo Medical University
• Principal Investigator: Iyama Satoshi 札幌医科大学, 医学部, 助教 (50398319)
• Co-Investigator(Kenkyū-buntansha): 佐藤 勉 札幌医科大学, 医学部, 講師 (40404602) ; 小船 雅義 札幌医科大学, 医学部, 准教授 (90336389)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 多発性骨髄腫 / DPP8/9

Outline of Final Research Achievements

Recently, the prognosis of patients with multiple myeloma (MM) has considerably improved due to the use of autologous hematopoietic stem cell transplantation and the introduction of new agents such as the immunomodulatory drugs, proteasome inhibitors. However, no curable treatment is available. We have previously shown that the DPP8/9 inhibitor, 1G244, induced MM cells to cell death by apoptosis. Hence, we demonstrated efficacy for treating MM with DPP8/9 inhibitor.

Free Research Field

造血器悪性腫瘍に対する治療